Author: admin

DelveInsight, “Hepatocellular Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Hepatocellular Carcinoma Pipeline Report

• DelveInsight’s Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.

• The leading companies working in the Hepatocellular Carcinoma Market include Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others.

• Promising Hepatocellular Carcinoma Pipeline Therapies in the various stages of development include lenvatinib, pembrolizumab (200 mg), Sorafenib, Enzalutamide, AZD9150, Nivolumab, and others.

• May 2024:- Translational Research in Oncology– A Phase III, Multicenter, Randomized, Open-label Trial to Evaluate the Safety and Efficacy of Systemic Therapy With Regorafenib and Pembrolizumab Versus Locoregional Therapy With Transarterial Chemoembolization or Transarterial Radioembolization, for the First-line Treatment of Intermediate-stage Hepatocellular Carcinoma With Beyond Up-to-7 Criteria.

• May 2024:- Target PharmSolutions Inc.– TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.

• May 2024:- BeiGene- A Phase 2 Study to Investigate the Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma. The primary objective of this study is to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC). 

Request a sample and discover the recent advances in Hepatocellular Carcinoma Treatment Drugs @ Hepatocellular Carcinoma Pipeline Outlook Report

In the Hepatocellular Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatocellular Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Hepatocellular Carcinoma Overview

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection. Cirrhosis is a significant step in viral carcinogenesis for hepatocellular carcinoma. Integration of the hepatitis B virus genome into the host genome is the primary pathogenesis for oncogenesis in HBV.

Find out more about Hepatocellular Carcinoma Treatment Landscape @ Drugs for Hepatocellular Carcinoma Treatment

Hepatocellular Carcinoma Emerging Drugs Profile

• Namodenoson: Can-Fite BioPharma

• SRF388: Surface Oncology

• Porustobart: Harbour BioMed

• Fisogatinib: CStone Pharmaceuticals

• STP705: Sirnaomics

Hepatocellular Carcinoma Pipeline Therapeutics Assessment

There are approx. 90+ key Hepatocellular Carcinoma companies which are developing the therapies for Hepatocellular Carcinoma. The Hepatocellular Carcinoma companies which have their Hepatocellular Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Can-Fite BioPharma.

DelveInsight’s Hepatocellular Carcinoma Pipeline Report covers around 95+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Learn more about the emerging Hepatocellular Carcinoma Pipeline Therapies @ Hepatocellular Carcinoma Clinical Trials Assessment

Scope of the Hepatocellular Carcinoma Pipeline Report

• Coverage- Global

• Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

• Hepatocellular Carcinoma Companies- Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others.

• Hepatocellular Carcinoma Pipeline Therapies- lenvatinib, pembrolizumab (200 mg), Sorafenib, Enzalutamide, AZD9150, Nivolumab, and others. 

Dive deep into rich insights for new drugs for Hepatocellular Carcinoma Treatment, Visit @ Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspective 

Table of Content

1. Introduction

2. Executive Summary

3. Hepatocellular Carcinoma: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Namodenoson: Can-Fite BioPharma

9. Drug profiles in the detailed report…..

10. Mid Stage Products (Phase II)

11. SRF388: Surface Oncology

12. Drug profiles in the detailed report…..

13. Early Stage Products (Phase I)

14. STP705: Sirnaomics

15. Drug profiles in the detailed report…..

16. Preclinical and Discovery Stage Products

17. Drug name: Company name

18. Drug profiles in the detailed report…..

19. Inactive Products

20. Hepatocellular Carcinoma Key Companies

21. Hepatocellular Carcinoma Key Products

22. Hepatocellular Carcinoma- Unmet Needs

23. Hepatocellular Carcinoma- Market Drivers and Barriers

24. Hepatocellular Carcinoma- Future Perspectives and Conclusion

25. Hepatocellular Carcinoma Analyst Views

26. Hepatocellular Carcinoma Key Companies

27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatocellular Carcinoma Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

DelveInsight, “Hypertension Pipeline Insight 2024” report provides comprehensive insights about 100+ Hypertension companies and 100+ pipeline drugs in Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hypertension therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from Hypertension Pipeline Report

• DelveInsight’s Hypertension pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Hypertension treatment.

• The leading companies working in the Hypertension Market include Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics Inc., Aadi Bioscience Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio Inc., and others.

• Promising Hypertension Pipeline Therapies in the various stages of development include Irbesartan/HCTZ, Riociguat (Adempas, BAY63-2521), Bisoprolol, Atenolol, Tadalafil, LCI699, Eplerenone, and others.

• April 2024:- Laboratorios Silanes SA De CV- Phase IIIb, randomized, double-blind, prospective, multicenter study to evaluate the efficacy and safety of the fixed-dose combination of losartan / chlorthalidone compared with losartan / hydrochlorothiazide in the treatment of patients with essential arterial hypertension.

• April 2024:- Servier Russia- DescripTion of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/atoRvastatin/Perindopril sinGle Pill Combination trEatmenT in Patients With Arterial Hypertension and Dyslipidemia in the Daily Clinical Practice. (TARGET). This is a multi-centre, observational, ambispective study, which will retrospectively and prospectively collect clinical and socio-demographic data from medical records of patients with HTN and dyslipidemia initiated with SPC of amlodipine/atorvastatin/perindopril in real clinical settings.

• April 2024:- Cereno Scientific AB- A Phase 2, Prospective, Randomized, Open-label, Blinded Endpoint, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of 3 Doses of CS1 in Subjects With Pulmonary Arterial Hypertension. This is a Phase 2, parallel group study to evaluate the safety, tolerability, PK, and exploratory efficacy of 3 doses of CS1 in the treatment of PAH using the CardioMEMS HF System to obtain repeated measurements of PAP and other hemodynamic parameters.

Request a sample and discover the recent advances in Hypertension Treatment Drugs @ Hypertension Pipeline Report

In the Hypertension pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Hypertension Overview

Hypertension is the most common primary diagnosis in the United States. It affects approximately 86 million adults (≥20 years) in the United States and is a major risk factor for stroke, myocardial infarction, vascular disease, and chronic kidney disease. Hypertension is defined as a systolic blood pressure (SBP) of 140 mm Hg or more, or a diastolic blood pressure (DBP) of 90 mm Hg or more, or taking antihypertensive medication.

Find out more about Hypertension Therapeutics Assessment @ Hypertension Preclinical and Discovery Stage Products

Hypertension Emerging Drugs Profile

• Firibastat: Quantum Genomics

• Baxdrostat (CIN-107): CinCor Pharma

• MLS-101: Mineralys Therapeutics

• Zilebesiran (ALN-AGT): Alnylam Therapeutics

• IONIS-AGT-LRx: Ionis Pharmaceuticals 

Hypertension Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the Hypertension therapies. The Hypertension companies which have their Hypertension drug candidates in the most advanced stage, i.e. phase III include, Reata Pharmaceuticals.

DelveInsight’s Hypertension pipeline report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation

• Inhalation/Intravenous/Oral

• Intranasal

• Intravenous

• Intravenous/ Subcutaneous

• NA

• Oral

• Oral/intranasal/subcutaneous

• Parenteral

• Subcutaneous

Hypertension Pipeline Products have been categorized under various Molecule types such as

• Antibody

• Antisense oligonucleotides

• Immunotherapy

• Monoclonal antibody

• Peptides

• Protein

• Recombinant protein

• Small molecule

• Stem Cell

• Vaccine

Learn more about the emerging Hypertension Pipeline Therapies @ Hypertension Clinical Trials Assessment

Scope of the Hypertension Pipeline Report

• Coverage- Global

• Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

• Hypertension Companies- Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics Inc., Aadi Bioscience Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio Inc., and others.

• Hypertension Pipeline Therapies- Irbesartan/HCTZ, Riociguat (Adempas, BAY63-2521), Bisoprolol, Atenolol, Tadalafil, LCI699, Eplerenone, and others.

Dive deep into rich insights for new drugs for Hypertension Treatment, Visit @ Hypertension Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction

2. Executive Summary

3. Hypertension: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Hypertension – DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Firibastat: Quantum Genomics

9. Drug profiles in the detailed report…..

10. Mid Stage Products (Phase II)

11. Baxdrostat (CIN-107): CinCor Pharma

12. Drug profiles in the detailed report…..

13. Early Stage Products (Phase I)

14. ID-140009: IlDong Pharmaceutical

15. Drug profiles in the detailed report…..

16. Preclinical and Discovery Stage Products

17. CKD 331: Chong Kun Dang

18. Drug profiles in the detailed report…..

19. Inactive Products

20. Hypertension Key Companies

21. Hypertension Key Products

22. Hypertension- Unmet Needs

23. Hypertension- Market Drivers and Barriers

24. Hypertension- Future Perspectives and Conclusion

25. Hypertension Analyst Views

26. Hypertension Key Companies

27. Appendix

For further information on the Hypertension Pipeline therapeutics, reach out to Hypertension Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hypertension Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

DelveInsight, “Liver Cancer Pipeline Insight 2024” report provides comprehensive insights about 70+ Liver Cancer companies and 75+ pipeline drugs in the Liver Cancer pipeline landscape. It covers the Liver Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Liver Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Liver Cancer Pipeline Report

• DelveInsight’s Liver Cancer Pipeline analysis depicts a robust space with 70+ active players working to develop 75+ pipeline treatment therapies.

• The leading Liver Cancer Companies working in the market include Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co, Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics, Novita Pharmaceuticals, and Bristol-Myers Squibb, and others.

• Promising Liver Cancer Therapies in the various stages of development include Atezolizumab, Bevacizumab, Tiragolumab, OH2 injection, MTL-CEBPA, Sorafenib 200mg, Lipiodol, Pemetrexed, Exatecan Mesylate, Brivanib, and others.

• May 2024:- Target PharmaSolutions Inc.- A Longitudinal Observational Study of the Natural History and Management of Patients With Hepatocellular Carcinoma.  TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.

• May 2024:- Eureka Therapeutics Inc.– An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-3). This is an open-label, dose escalation, multi-center, Phase I/II clinical trial. The purpose of this study is to evaluate an investigational ARTEMIS® ECT204 T-cell therapy in adult patients with GPC3-positive advanced hepatocellular carcinoma (HCC). In this study, a patient’s T cells are collected and genetically modified to express Eureka’s proprietary anti-GPC3 ARTEMIS T cell receptors (AbTCR). These modified T cells are then reintroduced into the patient to specifically seek out and destroy GPC3-expressing cancer cells.

Request a sample and discover the recent advances in Liver Cancer Treatment Drugs @ Liver Cancer Pipeline Outlook Report

In the Liver Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Liver Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Liver Cancer Overview

Liver cancer is a cancer that originates in the liver, and is an aggressive tumor that frequently occurs in the setting of chronic liver disease and cirrhosis. Primary liver cancer, or hepatocellular carcinoma (HCC), is the fifth most common cancer in males and the seventh most common cancer in females, and is the third leading cause of cancer-related death worldwide. Hepatocellular carcinoma (HCC), the primary cancer of the liver, is derived from hepatocytes and occurs in more than approximately 80% of cases of liver cancer. The HCC carcinogenesis is often associated with liver cirrhosis resulting from chronic liver diseases such as chronic hepatitis, HBV or HCV infection, and autoimmune hepatitis. .

Liver Cancer Emerging Drugs Profile

• Namodenoson: Can-Fite BioPharma

Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5′- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). Namodenoson’s mechanism of action is mediated via deregulation of the NF-κB and Wnt signal transduction pathways, resulting in the apoptosis of tumor cells. The protective effect of Namodenoson is mediated via down-regulation of the NF-kB signal transduction pathway and preventing apoptosis. Namodenoson has a potent anti-cancer effect, particularly against hepatocellular carcinoma, and anti-inflammatory activity demonstrated in pre-clinical animal models of liver inflammation.

• YIV-906: Yiviva

YIV-906 (also PHY906 or KD018) is a therapeutic candidate comprised of a proprietary cGMP botanical extract of four herbs inspired by a traditional Chinese medicine formulation used for over a millennium. YIV-906 has the potential to be developed as a platform oncology therapeutic when administered in combination with chemotherapy, immunotherapy and radiation therapies, in multiple cancer indications. YIV-906 has been shown to enhance immune function in the tumor microenvironment (by polarizing M1 macrophages and activating T cells), protect the gastrointestinal tract (by inhibiting inflammation via IL-6, NF-kappa-B, COX2, and iNOS pathways) and promote intestinal tissue repair (by increasing activity and expression of components of the Wnt signaling pathway). YIV-906 has been observed to enhance the anti-tumor activity of sorafenib in preclinical models of hepatocellular carcinoma and has shown promise in preliminary clinical studies in liver, pancreatic, colorectal and rectal cancers. Currently, the drug is in Phase II stage of its clincal trial for the treatment of liver cancer.

• TTI-101: Tvardi Therapeutics

TTI-101 is an orally bioavailable, small-molecule inhibitor of signal transducer and activator of transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis. Preclinically, TTI-101 has demonstrated an excellent pharmacokinetic profile, potency in attenuating pY705-STAT3 phosphorylation, and efficacy in inhibiting tumor growth in xenograft and syngeneic tumor models. Currently, the drug is in the Phase II stage of clinical trial.

• STP707: Sirnaomics

STP707, our second key product, is in early-stage development for the treatment of solid tumors, liver cancer. STP707 is an intravenously administered TGF-ß1 and COX-2 inhibitor that leverages an RNAi-based response using the company’s proprietary PNP delivery platform. Currently, the drug is in Phase I stage of its clinical trial for the treatment of liver cancer.

Learn more about Liver Cancer in Clinical Trials @ Liver Cancer Drugs

Liver Cancer Therapeutics Assessment

There are approx. 70+ key Liver Cancer companies which are developing the therapies Liver Cancer. The Liver Cancer companies which have their Liver Cancer drug candidates in the most advanced stage, i.e. phase III include, Can-Fite BioPharma.

DelveInsight’s Liver Cancer pipeline report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Discover more about Liver Cancer in development @ Liver Cancer Clinical Trials

Liver Cancer Companies

Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co, Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics, Novita Pharmaceuticals, and Bristol-Myers Squibb, and others.

Liver Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Liver Cancer Products have been categorized under various Molecule types such as

• Oligonucleotide

• Peptide

• Small molecule

To know more about Liver Cancer, visit @ Liver Cancer Segmentation

Scope of the Liver Cancer Pipeline Report

• Coverage- Global

• Liver Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Liver Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

• Liver Cancer Companies- Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co, Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics, Novita Pharmaceuticals, and Bristol-Myers Squibb, and others.

• Liver Cancer Therapies- Atezolizumab, Bevacizumab, Tiragolumab, OH2 injection, MTL-CEBPA, Sorafenib 200mg, Lipiodol, Pemetrexed, Exatecan Mesylate, Brivanib, and others.

For further information on the Liver Cancer Pipeline Therapeutics, reach out @ Liver Cancer Products Development

Table of Content

1. Introduction

2. Executive Summary

3. Liver Cancer: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Liver Cancer – DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Namodenoson: Can-Fite BioPharma

9. Drug profiles in the detailed report…..

10. Mid Stage Products (Phase II)

11. YIV-906: Yiviva

12. Drug profiles in the detailed report…..

13. Early Stage Products (Phase I)

14. STP707: Sirnaomics

15. Mid Stage Products (Phase II)

16. Preclinical Stage Products

17. Drug Name: Company Name

18. Drug profiles in the detailed report…..

19. Inactive Products

20. Liver Cancer – Collaborations Assessment- Licensing / Partnering / Funding

21. Liver Cancer – Unmet Needs

22. Liver Cancer – Market Drivers and Barriers

23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Liver Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

DelveInsight, “Hemophilia Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hemophilia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Hemophilia Pipeline Report

• DelveInsight’s Hemophilia pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Hemophilia treatment.

• The leading Hemophilia Companies working in the market include Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, and Bioverativ, and others.

• Promising Hemophilia Therapies in the various stages of development include ELOCTA, ALPROLIX, Mim8, NNC0365-3769, MG1113, STSP-0601 for Injection, SerpinPC, Fitusiran, Esperoct, and others.

• May 2024:- Novo Nordisk A/S- A Multinational, Open-label, Randomised, Controlled Study to Investigate Efficacy and Safety of NNC0365-3769 (Mim8) in Adults and Adolescents With Haemophilia A With or Without Inhibitors. This study is investigating how Mim8 works compared to other medicines in people with hemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used for prevention of bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII).

• May 2024:- Takeda– The main aim is to describe how the treatment burden and challenges of participants, relatives, and doctors during regular Factor VIII and Factor IX infusions to treat hemophilia evolve using a virtual-reality (VR) based solution. The study also aims to find out how well the VR based solution is tolerated and how satisfied the participants, relatives, and doctors are with it.

• May 2024:- Laboratoire français de Fractionnement et de Biotechnologies– A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures. This is an interventional, prospective, international, multicenter, single-arm, Phase 3, and sequential efficacy and safety study in adolescents and adults with congenital hemophilia A or B with inhibitors to factor VIII (FVIII) or factor IX (FIX) undergoing elective major surgical procedures.

• May 2024:- Hoffmann-La Roche- A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A. Study WP44714 is a Phase I/II, open-label, non-randomized, global, multicenter, multiple-ascending dose (MAD) study in adult and adolescent male participants with severe or moderate hemophilia A with or without factor VIII (FVIII) inhibitors. The aim is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of multiple ascending doses of NXT007.

• May 2024:- Regeneron Pharmaceuticals– A Prospective Study to Evaluate Disease Characteristics in Hemophilia B Participants Receiving Prophylaxis With Standard of Care FIX Replacement Therapy. This study is focused on males who have Hemophilia B and who need regular preventive treatment with factor IX protein (FIX) replacement therapy to prevent and also to control their bleeding events. The aim of the study is to gather at least 6 months of information on bleeding events for each individual participant while they continue to use their usual FIX replacement therapy.

Request a sample and discover the recent advances in Hemophilia @ Hemophilia Pipeline Outlook Report

Hemophilia Overview

Hemophilia is usually an inherited bleeding disorder in which the blood doesn’t clot properly. This can lead to spontaneous bleeding as well as bleeding following injuries or surgery. Blood contains many proteins called clotting factors that can help to stop bleeding. People with hemophilia have low levels of either factor VIII (8) or factor IX (9). The severity of hemophilia that a person has is determined by the amount of factors in the blood. The lower the amount of the factor, the more likely it is that bleeding will occur which can lead to serious health problems. 

Hemophilia Emerging Drugs Profile

• SerpinPC: Centessa Pharmaceuticals

SerpinPC, a specific inhibitor of activated protein C (APC), for the treatment of hemophilia A and hemophilia B. SerpinPC has been observed to be well-tolerated in the clinical setting, associated with promising reductions in bleeding rates, and has PK suitable for infrequent subcutaneous dosing without the need for factor replacement. SerpinPC has human genetic target validation and established proof of concept Phase 2a clinical data.

• Fitusiran: Alnylam Pharmaceuticals

Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in development for the treatment of hemophilia and rare bleeding disorders (RBDs) by their collaborators at Sanofi Genzyme. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Hemophilia.

• ASC 618: ASC Therapeutics

ASC618 is an AAV8-based gene therapy for the treatment of hemophilia A, affecting approximately 1 of every 5000 live-born males. ASC618 incorporates a novel liver-specific promoter and a bioengineered, codon-optimized B domain-deleted FVIII variant; in preclinical studies, ASC618 exhibits at least a 10-fold increase in the biosynthesis and secretion of FVIII compared with native human FVIII bioengineered gene constructs. ASC618 has the potential to increase durability of clotting factor biosynthesis and secretion by minimizing cellular stress and induction of the unfolded protein response, which may lead to diminished FVIII production from liver cells.

Learn more about Hemophilia in clinical trials @ Hemophilia Drugs

Hemophilia Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Hemophilia. The companies which have their Hemophilia drug candidates in the most advanced stage, i.e. Phase III includes Alnylam Pharmaceuticals.

DelveInsight’s Hemophilia Pipeline Report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Discover more about Hemophilia in development @ Hemophilia Clinical Trials

Hemophilia Companies

Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, and Bioverativ, and others.

Hemophilia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Hemophilia Products have been categorized under various Molecule types such as

• Oligonucleotide

• Peptide

• Small molecule

To know more about Hemophilia, visit @ Hemophilia Segmentation

Scope of the Hemophilia Pipeline Report

• Coverage- Global

• Hemophilia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Hemophilia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

• Hemophilia Companies- Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, and Bioverativ, and others.

• Hemophilia Therapies- ELOCTA, ALPROLIX, Mim8, NNC0365-3769, MG1113, STSP-0601 for Injection, SerpinPC, Fitusiran, Esperoct, and others.

For further information on the Hemophilia Pipeline Therapeutics, reach out @ Hemophilia Products Development

Table of Content

1. Introduction

2. Executive Summary

3. Hemophilia: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Hemophilia– DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Fitusiran: Alnylam Pharmaceuticals

9. Drug profiles in the detailed report…..

10. Mid Stage Products (Phase II)

11. SerpinPC: Centessa Pharmaceuticals

12. Drug profiles in the detailed report…..

13. Early Stage Products (Phase I)

14. Drug name: Company Name

15. Drug profiles in the detailed report…..

16. Preclinical and Discovery Stage Products

17. Drug name: Company Name

18. Drug profiles in the detailed report…..

19. Inactive Products

20. Hemophilia Key Companies

21. Hemophilia Key Products

22. Hemophilia- Unmet Needs

23. Hemophilia- Market Drivers and Barriers

24. Hemophilia- Future Perspectives and Conclusion

25. Hemophilia Analyst Views

26. Hemophilia Key Companies

27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hemophilia Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

DelveInsight, “Hepatitis B Virus Infection Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Hepatitis B Virus Infection pipeline landscape. It covers the Hepatitis B Virus Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatitis B Virus Infection pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Hepatitis B Virus Infection Pipeline Report

• DelveInsight’s Hepatitis B Virus Infection pipeline report depicts a robust space with 80+ active players working to develop 90+ pipeline therapies for Hepatitis B Virus Infection treatment.

• The leading companies working in the Hepatitis B Virus Infection Market include Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics, and others.

• Promising Hepatitis B Virus Infection Pipeline Therapies in the various stages of development include BRII-835, EYP001a, VIR-2218, Pegylated interferon-alfa 2a, ABI-H3733, and others.

• May 2024:- Biolytical Labotories– A Prospective Cross-Sectional Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Site Settings. Participants are prospctively recruited and enrolled to participate in the study. The Capillary (fingerstick) whole blood, and venous whole blood samples (in serum separating tube (SST) and Ethylenediaminetetraacetic acid (EDTA) tube) are collected by a healthcare professional.

• May 2024:- Gilead Sciences– A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects With Chronic Hepatitis B Virus Infection. The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children. 

Request a sample and discover the recent advances in Hepatitis B Virus Infection Treatment Drugs @ Hepatitis B Virus Infection Pipeline Report

In the Hepatitis B Virus Infection pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatitis B Virus (HBV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Hepatitis B Virus Infection Overview

Hepatitis B viral infection is a serious global healthcare problem. It is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). Hepatitis B virus is transmitted via percutaneous inoculation or through mucosal exposure with infectious bodily fluids. Oral-fecal transmission is possible but considerably rare.

Find out more about Hepatitis B Virus Infection Therapeutics Assessment @ Hepatitis B Virus Infection Preclinical and Discovery Stage Products

 Hepatitis B Virus Infection Emerging Drugs Profile

• Bepirovirsen: GSK

• VIR 2218: Vir Biotechnology

• AB 729: Arbutus Biopharma

• AHB-137: Ausper Biopharma

Hepatitis B Virus Infection Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the Hepatitis B Virus Infection. The Hepatitis B Virus Infection companies which have their Hepatitis B Virus Infection drug candidates in the most advanced stage, i.e. phase III include GSK.

DelveInsight’s Hepatitis B Virus Infection pipeline report covers around 90+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Hepatitis B Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Hepatitis B Virus Infection Pipeline Products have been categorized under various Molecule types such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Learn more about the emerging Hepatitis B Virus Infection Pipeline Therapies @ Hepatitis B Virus Infection Clinical Trials Assessment

Scope of the Hepatitis B Virus Infection Pipeline Report

• Coverage- Global

• Hepatitis B Virus Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Hepatitis B Virus Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

• Hepatitis B Virus Infection Companies- Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics, and others.

• Hepatitis B Virus Infection Pipeline Therapies- BRII-835, EYP001a, VIR-2218, Pegylated interferon-alfa 2a, ABI-H3733, and others.

Dive deep into rich insights for new drugs for Hepatitis B Virus Infection Treatment, Visit @ Hepatitis B Virus Infection Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction

2. Executive Summary

3. Hepatitis B Virus Infection: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Hepatitis B Virus Infection– DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Bepirovirsen: GSK

9. Drug profiles in the detailed report…..

10. Mid Stage Products (Phase II)

11. VIR 2218: Vir Biotechnology

12. Drug profiles in the detailed report…..

13. Early Stage Products (Phase I)

14. AHB-137: Ausper Biopharma

15. Drug profiles in the detailed report…..

16. Preclinical and Discovery Stage Products

17. Drug name: Company name

18. Drug profiles in the detailed report…..

19. Inactive Products

20. Hepatitis B Virus Infection Key Companies

21. Hepatitis B Virus Infection Key Products

22. Hepatitis B Virus Infection- Unmet Needs

23. Hepatitis B Virus Infection- Market Drivers and Barriers

24. Hepatitis B Virus Infection- Future Perspectives and Conclusion

25. Hepatitis B Virus Infection Analyst Views

26. Hepatitis B Virus Infection Key Companies

27. Appendix

For further information on the Hepatitis B Virus Infection Pipeline therapeutics, reach out to Hepatitis B Virus Infection Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatitis B Virus (HBV) Infection Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

DelveInsight, “Esophageal Cancer Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Esophageal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Esophageal Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Esophageal Cancer Pipeline Report

• DelveInsight’s Esophageal Cancer pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Esophageal Cancer treatment.

• The leading Esophageal Cancer Companies working in the market include BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., and others.

• Promising Esophageal Cancer Therapies in the various stages of development include Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, trastuzumab and others.

• May 2024:- Merck Sharp & Dohme LLC- A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590). The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus standard of care (SOC) chemotherapy with cisplatin and 5-fluorouracil (5-FU) versus placebo plus SOC chemotherapy with cisplatin and 5-FU as first-line treatment in participants with locally advanced or metastatic esophageal carcinoma.

• February 2024- Wuhan Ammunition Life-tech Co., Ltd- Methylation Detection of KCNA3 and OTOP2 Genes in Plasma for the Auxiliary Diagnosis of Esophageal Cancer/Precancerous Lesions: a Clinical Trial. Esophageal carcinoma is caused by abnormal hyperplasia of the squamous or glandular epithelium, the main pathological types are squamous cell carcinoma and adenocarcinoma. Globally, esophageal cancer has the seventh highest incidence and the sixth leading cause of cancer death. Statistics showed that in 2020, there were 604,000 new cases of esophageal cancer and 54.4 deaths.

• January 2024:- Jiangsu HengRui Medicine Co., Ltd.- A Randomized, Open-Label, Active-Controlled, Multi-Center, Phase III Clinical Study of Anti-PD-1 Antibody SHR-1210 vs. Investigator’s Choice of Chemotherapy in Subjects With Locally Advanced or Metastatic Esophageal Cancer. In this study, participants with advanced or metastatic squamous cell carcinoma of the esophagus that has progressed after first-line standard therapy will be randomized to receive either single agent SHR-1210 or the Investigator’s choice of standard therapy with docetaxel or irinotecan. The primary study hypothesis is that treatment with SHR-1210 will prolong overall survival (OS) as compared to treatment with standard therapy. 

Request a sample and discover the recent advances in Esophageal Cancer @ Esophageal Cancer Pipeline Outlook Report

Esophageal Cancer Overview

Esophageal cancer develops in the esophagus, which is the tube that connects the throat to the stomach. Tumors arise in the mucosa, which is the inner lining of the esophagus. There are two types of esophageal cancer, each with different risk factors: Adenocarcinoma -Cancers that start in gland cells at the bottom of the esophagus are called adenocarcinomas. This type of cancer is the most common esophageal cancer. It usually occurs closer to the stomach. Chronic acid reflux, gastroesophageal reflux disease (GERD), Barrett’s esophagus and chronic heartburn can increase the risk of developing adenocarcinoma esophageal cancer. 

Esophageal Cancer Emerging Drugs Profile

• AN-0025: Adlai Nortye

AN0025 is a clinical stage, potential first-in-class EP4 antagonist designed to modulate tumor microenvironment. It blocks the PGE2-EP4 signaling pathway to inhibit PGE2-mediated immunosuppression in the tumor microenvironment. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Esophageal Cancer.

• Tucatinib: Seagen

Tucatinib (TUKYSA®) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein, a protein that contributes to cancer cell growth.HER2 is overexpressed in multiple cancers, including breast, colorectal, and gastric cancers. In preclinical in vitro studies, TUKYSA inhibited phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell growth (proliferation), and showed anti-tumor activity in HER2-expressing tumor cells. In preclinical and clinical studies, TUKYSA inhibited the growth of HER2-expressing tumors. The combination of TUKYSA and the anti-HER2 antibody trastuzumab has also been shown to increase anti-tumor activity in vitro and in vivo compared to either medicine alone. Currently, the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Esophageal Cancer.

• APX 005M: Apexigen

APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of APX005M to CD40 on antigen presenting cells (i.e., dendritic cells, monocytes and B-cells) initiates a multi-faceted immune response bringing multiple components of the immune system (e.g., T cells, macrophages) to work in concert against cancer. APX005M is currently in Phase 2 clinical development for the treatment of cancers such as pancreatic cancer, esophageal and gastroesophageal junction cancers, melanoma, non-small cell lung cancer, rectal cancer and sarcoma in various combinations with immunotherapy, chemotherapy, radiation therapy or a cancer vaccine.

Learn more about Esophageal Cancer in clinical trials @ Esophageal Cancer Drugs

Esophageal Cancer Therapeutics Assessment

There are approx. 80+ key Esophageal Cancer companies which are developing the therapies for Esophageal Cancer. The Esophageal Cancer companies which have their Esophageal Cancer drug candidates in the most advanced stage, i.e. phase II/III include, Seagen.

DelveInsight’s Esophageal Cancer Pipeline Report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Discover more about Esophageal Cancer in development @ Esophageal Cancer Clinical Trials

Esophageal Cancer Companies

BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., and others.

Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Esophageal Cancer Products have been categorized under various Molecule types such as

• Oligonucleotide

• Peptide

• Small molecule

To know more about Esophageal Cancer, visit @ Esophageal Cancer Segmentation

Scope of the Esophageal Cancer Pipeline Report

• Coverage- Global

• Esophageal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Esophageal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

• Esophageal Cancer Companies- BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., and others.

• Esophageal Cancer Therapies-Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, trastuzumab and others.

For further information on the Esophageal Cancer Pipeline Therapeutics, reach out @ Esophageal Cancer Products Development

Table of Content

1. Introduction

2. Executive Summary

3. Esophageal Cancer: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Esophageal Cancer– DelveInsight’s Analytical Perspective

7. Late Stage Products (Pre-Registration)

8. Drug Name : Company Name

9. Drug profiles in the detailed report…..

10. Last Stage Products (Phase II/III)

11. Tucatinib: Seagen

12. Drug profiles in the detailed report…..

13. Mid Stage Products (Phase II)

14. APX 005M: Apexigen

15. Drug profiles in the detailed report…..

16. Preclinical and Discovery Stage Products

17. Drug Name : Company Name

18. Drug profiles in the detailed report…..

19. Inactive Products

20. Esophageal Cancer Key Companies

21. Esophageal Cancer Key Products

22. Esophageal Cancer – Unmet Needs

23. Esophageal Cancer – Market Drivers and Barriers

24. Esophageal Cancer – Future Perspectives and Conclusion

25. Esophageal Cancer Analyst Views

26. Esophageal Cancer Key Companies

27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Esophageal Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

DelveInsight, “Head and Neck cancer Pipeline Insight 2024” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the Head and Neck cancer pipeline landscape. It covers the Head and Neck cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Head and Neck cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key highlights from the Head and Neck Cancer Pipeline Report

• DelveInsight’s Head and Neck Cancer pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for Head and Neck Cancer treatment.

• The leading Head and Neck Cancer Companies working in the market includes Debiopharm/Merck, AstraZeneca/MedImmune, Eisai Co Ltd/Merck & Co, Kura Oncology, Cellectar Biosciences, Galera Therapeutics, Inc., BioMimetix JV, LLC, Bristol-Myers Squibb, QBiotics Group Limited, Alentis Therapeutics AG, Coordination Pharmaceuticals, Inc., Genmab, Merck Sharp & Dohme LLC, Immunovative Therapies, Ltd., TyrNovo Ltd, BioNTech SE, Aveta Biomics, Inc., Pfizer, and Cue Biopharma are prominent players within the pharmaceutical and biotech industries.

• Promising Head and Neck Cancer Therapies in the various stages of development include Gefitinib, Cisplatin, Fluorouracil, RiMO-301, Pembrolizumab, Erlotinib, and others.

• May 2024:- Ascendis Pharma Oncology– BelieveIT-201: Phase 2, Randomized Open-labeled Trial of TransCon (TC) TLR7/8 Agonist in Combination With Pembrolizumab or With TC IL-2 β/γ, or Pembrolizumab Alone as Neoadjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. The purpose of this trial is to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and pembrolizumab given prior to curative intent surgery in treatment of participants with newly diagnosed Stage III/IVA resectable locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC).

• April 2024:- M.D. Anderson Cancer Center– Randomized, Placebo-Controlled, Phase 2 Study Of Induction Chemotherapy With Cisplatin/Carboplatin, And Docetaxel With Or Without Erlotinib In Patients With Head And Neck Squamous Cell Carcinomas Amenable For Surgical Resection. The goal of this clinical research study is to learn if adding erlotinib to a standard chemotherapy combination (docetaxel and either cisplatin or carboplatin) can help to control SCCHN. The safety of this drug combination will also be studied.

Request a sample and discover the recent advances in Head and Neck Cancer @ Head and Neck Cancer Pipeline Outlook Report

Head and Neck Cancer Overview

Head and neck cancer is a collective term that includes several different types of cancers. Cancers of the head and neck are categorized by the area in which they begin. This includes the mouth (oral cavity), throat (pharynx), voice box (larynx), sinuses and nose cavity, and salivary glands. The most common type of head and neck cancer is squamous cell carcinoma of the head and neck (HNSCCA). Most HNSCCA begins in the layer of flat cells (the epithelium) which line the structures of the upper aero digestive tract, including the mouth, throat, and voice box. 

Head and Neck Cancer Emerging Drugs Profile

• Xevinapant : Merck

Xevinapant is a potent, orally available, inhibitor of IAPs (Inhibitor of Apoptosis Proteins). IAP inhibitors restore sensitivity to apoptosis in cancer cells and thereby deprive them of one of their major resistance mechanisms. The drug is under an exclusive license agreement with Merck. Xevinapant received FDA granted Breakthrough Therapy Designation. Currently it is in Phase III stage of clinical trial evaluation to treat Head and Neck Cancer.

• Durvalumab : AstraZeneca

Durvalumab (MEDI4736) is an investigational human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumors avoid detection by the immune system. The drug blocks these signals, countering the tumor’s immune-evading tactics. MEDI4736 is being developed, alongside other immunotherapies, to empower the patient’s immune system and attack the cancer. Currently being evaluated in the Phase III studies for the treatment of head and neck cancer.

• Tipifarnib : Kura Oncology

Tipifarnib is an oral, small molecule drug candidate and highly selective inhibitor of farnesyltransferase. The drug is in the Phase II stage of clinical trials for the treatment of head and neck cancer.

• Iopofosine: Cellectar Biosciences

Lopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. The drug is being developed in collaboration with University of Wisconsin-Madison. The drug is in Phase I stage of clinical trials for the treatment of head and neck cancer.

Learn more about Head and Neck Cancer in clinical trials @ Head and Neck Cancer Drugs

Head and Neck Cancer Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Head and Neck cancer. The companies which have their Head and Neck cancer drug candidates in the most advanced stage, i.e. phase III include, Merck.

DelveInsight’s Head and Neck Cancer Pipeline Report covers around 120+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Discover more about Head and Neck Cancer in development @ Head and Neck Cancer Clinical Trials

Head and Neck Cancer Companies

Debiopharm/Merck, AstraZeneca/MedImmune, Eisai Co Ltd/Merck & Co, Kura Oncology, Cellectar Biosciences, Galera Therapeutics, Inc., BioMimetix JV, LLC, Bristol-Myers Squibb, QBiotics Group Limited, Alentis Therapeutics AG, Coordination Pharmaceuticals, Inc., Genmab, Merck Sharp & Dohme LLC, Immunovative Therapies, Ltd., TyrNovo Ltd, BioNTech SE, Aveta Biomics, Inc., Pfizer, and Cue Biopharma and others.

Head and Neck cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Head and Neck Cancer Products have been categorized under various Molecule types such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

To know more about Head and Neck Cancer , visit @ Head and Neck Cancer Segmentation

Scope of the Head and Neck Cancer Pipeline Report

• Coverage- Global

• Head and Neck Cancer Companies- Debiopharm/Merck, AstraZeneca/MedImmune, Eisai Co Ltd/Merck & Co, Kura Oncology, Cellectar Biosciences, Galera Therapeutics, Inc., BioMimetix JV, LLC, Bristol-Myers Squibb, QBiotics Group Limited, Alentis Therapeutics AG, Coordination Pharmaceuticals, Inc., Genmab, Merck Sharp & Dohme LLC, Immunovative Therapies, Ltd., TyrNovo Ltd, BioNTech SE, Aveta Biomics, Inc., Pfizer, and Cue Biopharma and others.

• Head and Neck Cancer Therapies- Gefitinib, Cisplatin, Fluorouracil, RiMO-301, Pembrolizumab, Erlotinib, and others.

• Head and Neck Cancer Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For further information on the Head and Neck Cancer Pipeline Therapeutics, reach out @ Head and Neck Cancer Products Development

Table of Content

1. Introduction

2. Executive Summary

3. Head and Neck Cancer : Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Late Stage Products (Phase III)

7. Xevinapant : Merck

8. Drug profiles in the detailed report…..

9. Mid Stage Products (Phase II)

10. Tipifarnib : Kura Oncology

11. Early Stage Products (Phase I)

12. Iopofosine : Cellectar Biosciences

13. Inactive Products

14. Head and Neck Cancer Key Companies

15. Head and Neck Cancer Key Products

16. Head and Neck Cancer – Unmet Needs

17. Head and Neck Cancer – Market Drivers and Barriers

18. Head and Neck Cancer – Future Perspectives and Conclusion

19. Head and Neck Cancer Analyst Views

20. Head and Neck Cancer Key Companies

21. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Head and Neck cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

DelveInsight, “Eczema Pipeline Insight 2024” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Eczema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Eczema Pipeline Report

• DelveInsight’s Eczema pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Eczema treatment.

• The leading Eczema Companies working in the market include Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.

• Promising Eczema Therapies in the various stages of development include Mucopolysaccharide Polysulfate Cream, ZL-3101, alitretinoin, LAS41003, Clobetasone Butyrate 0.05% Cream, and others.

• May 2024:- Arcutis Biotherapeutics Inc.- A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects With Atopic Dermatitis. This study will assess the safety and efficacy of ARQ-151 cream vs vehicle applied once a day for 4 weeks by subjects with atopic dermatitis (eczema).

• May 2024:- Incyte Corporation- A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis. This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.

• May 2024:- Apogee Therapeutics Inc- A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients with Moderate-to-severe Atopic Dermatitis. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B.

Request a sample and discover the recent advances in Eczema @ Eczema Pipeline Outlook Report

Eczema Overview

Eczema, also known as atopic dermatitis, is the most common form of dermatitis. Genetic as well as environmental factors are thought to play a part in the pathogenesis. Eczema is most commonly seen in children but can be seen in adults. People with the disease tend to have dry, itchy skin that is prone to infection. Eczema is commonly known as the “”itch that rashes”” due to dry skin that leads to a rash as a result of scratching or rubbing. The most important treatment of eczema is skin hydration followed by topical steroids for flare-ups.

Eczema Emerging Drugs Profile

• Amlitelimab: Kymab

Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases.

• BX 005: BiomX

BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

• LP 0145: LEO Pharma

LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczemas.

Learn more about Eczema in clinical trials @ Eczema Drugs

Eczema Therapeutics Assessment

There are approx. 100+ Eczema companies which are developing the Eczema therapies. The Eczema companies which have their Eczema drug candidates in the most advanced stage, i.e. phase II include, LEO Pharma.

DelveInsight’s Eczema Pipeline Report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Discover more about Eczema in development @ Eczema Clinical Trials

Eczema Companies

Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.

Eczema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

To know more about Eczema, visit @ Eczema Segmentation

Scope of the Eczema Pipeline Report

• Coverage- Global

• Eczema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Eczema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

• Eczema Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others. 

• Eczema Therapies-Mucopolysaccharide Polysulfate Cream, ZL-3101, alitretinoin, LAS41003, Clobetasone Butyrate 0.05% Cream, and others.

For further information on the Eczema Pipeline Therapeutics, reach out @ Eczema Products Development

Table of Content

1. Introduction

2. Executive Summary

3. Eczema: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Eczema– DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Drug name : Company name

9. Drug profiles in the detailed report…..

10. Mid Stage Products (Phase II)

11. Amlitelimab: Kymab

12. Drug profiles in the detailed report…..

13. Early Stage Products (Phase I)

14. Drug name : Company name

15. Drug profiles in the detailed report…..

16. Preclinical and Discovery Stage Products

17. Drug name : Company name

18. Drug profiles in the detailed report…..

19. Inactive Products

20. Eczema Key Companies

21. Eczema Key Products

22. Eczema- Unmet Needs

23. Eczema- Market Drivers and Barriers

24. Eczema- Future Perspectives and Conclusion

25. Eczema Analyst Views

26. Eczema Key Companies

27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Eczema Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)